Anavex Life Sciences

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Anavex Life Sciences reports Q1 results, highlights precision medicine focus

Anavex Life Sciences showcased positive results in the Alzheimer's study and emphasized precision medicine in addressing neurological disorders.
The company's financial performance, with a net loss of $13 million and a cash position of $143.6 million, reflects ongoing research and development efforts.
Challenges include financial losses, regulatory discussions, and operational complexities, while opportunities lie in upcoming data readouts and new clinical trials.
Overall, Anavex's strategic focus on precision medicine and diverse pipeline position it for potential growth and advancements in neurological treatments.

Anavex Life Sciences reports Q2 results, eyes pipeline expansion

Anavex Life Sciences reported a mixed financial performance in Q2 2023 but maintains a strong cash position for future operations and clinical programs.
The company's focus on Alzheimer's disease treatments, pipeline expansion, and team strengthening reflect a commitment to advancing innovative therapies.
While facing financial challenges and competitive pressures, Anavex has opportunities to leverage its clinical successes, new hires, and partnerships for future growth.

Anavex Life Sciences reports Q3 loss, eyes neurology breakthroughs

Anavex Life Sciences is actively pursuing clinical advancements in neurology with a focus on blarcamesine. Despite financial challenges, the company's strategic partnerships and pipeline expansion position it well for future growth and innovation.

Anavex Life Sciences reports strong cash position amidst strategic focus

Anavex Life Sciences demonstrated financial strength with a substantial cash position in Q4 2023, while facing challenges with a net loss.
The company's strategic focus on precision medicine programs and ongoing trials presents opportunities for growth and innovation in the healthcare sector.
Navigating regulatory processes and balancing financial sustainability will be key for Anavex to capitalize on its strengths and address operational challenges.

Anavex Life Sciences reports Q1 loss but advances precision medicine

Anavex Life Sciences reported financials reflecting a net loss but with a solid cash position, emphasizing fiscal responsibility and ongoing research progress.
The company's strengths lie in its financial stability, innovative precision medicine focus, and commitment to addressing neurological disorders.
Challenges include managing financial losses, meeting regulatory timelines, and balancing fiscal prudence with research investments.
Opportunities arise from upcoming submissions, precision medicine trends, therapeutic expansion, and potential collaborations.

Anavex Life Sciences reports Q2 progress amidst analyst inquiries

Anavex Life Sciences is actively pursuing the development of therapies for various neurological disorders. The company faces challenges in FDA guidance interpretation, European filings, and commercialization strategies. However, with a solid cash position and a focus on transformative therapies, Anavex has significant growth opportunities.

Anavex Life Sciences reports Q3 results, advances precision medicine

Anavex Life Sciences showcased financial stability with a strong cash position despite reporting a net loss, underlining their commitment to advancing treatments for brain disorders.
Progress in trials for blarcamesine in Alzheimer's disease and other neurological conditions signals potential breakthroughs in precision medicine.
While facing challenges such as managing losses and regulatory uncertainties, Anavex remains poised to leverage opportunities through upcoming data releases and regulatory submissions.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Anavex has two big catalysts coming up, both in Alzheimer's disease and Parkinson's Disease Dementia. Results reported so far show long-lasting cognition changes, and I am expecting Anavex to report improvement in cognition of patients on the upcoming trial readout.

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Treatments such as Aricept and likely simufilam that inhibit the formation of the nitro-oxidant peroxynitrite and speed its decomposition stabilize Alzheimer's disease for about a year. Treatments (blarcamesine, Trappsol Cyclo, panax ginseng) that inhibit the formation of peroxynitrite, scavenge it, and reverse part of its damage largely stabilize Alzheimer's disease for long periods of time.

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer's Disease

Recent research is claiming pivotal study data was falsified in order to bolster the amyloid hypothesis. This should have a positive impact on Alzheimer's programs based on other mechanisms.

Anavex And The Debunking Of The Amyloid Hypothesis

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q3 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Clint Tomlinson - IR Dr. Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Yun Zhong - BTIG Raghuram Selvaraju - H.C. Wainwright Clint Tomlinson Good afternoon.

Anavex Life Sciences Corp. (AVXL) CEO Dr. Christopher Missling on Q3 2022 Results - Earnings Call Transcript

Company to host a webcast today at 4:30 p.m. Eastern Time

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results

Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday August 9, 2022, 4:30 pm ET

Anavex Life Sciences to Announce Fiscal 2022 Third Quarter Financial Results on Tuesday August 9, 2022

ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01) ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01)

Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer's Disease at AAIC 2022

Expression levels of pathological dysregulated neurodegenerative genes of both Alzheimer's and Parkinson's disease were significantly restored by the therapeutic effect of ANAVEX®2-73 (p

Anavex Announces First Entire Clinical Alzheimer's Gene Pathway Data of ANAVEX®2-73 at AAIC 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 179.5% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Anavex Life Sciences (AVXL) Could Surge 179%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 238.3% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Anavex Life Sciences (AVXL) Could Rally 238%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 286.4% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Anavex Life Sciences (AVXL)? Wall Street Analysts Think 286%

Publication Demonstrates the Feasibility to Use Blood Biomarkers to Monitor Response to ANAVEX®2-73 (blarcamesine) in Clinical Trials of Fragile X Syndrome (Major Cause of Autism) Publication Demonstrates the Feasibility to Use Blood Biomarkers to Monitor Response to ANAVEX®2-73 (blarcamesine) in Clinical Trials of Fragile X Syndrome (Major Cause of Autism)

Anavex's Publication Supports Clinical Biomarker for ANAVEX®2-73 in Fragile X Syndrome

Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release.

Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease

As the recent Rett syndrome controversy shows, Anavex is a perpetually beleaguered stock. Despite the tremendous bearish headwind it always faces, the company has been able to increase shareholder value over the years.

Anavex: Increasing Shareholder Value Against All Odds

The average of price targets set by Wall Street analysts indicates a potential upside of 265% in Anavex Life Sciences (AVXL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Anavex Life Sciences (AVXL) Have the Potential to Rally 265% as Wall Street Analysts Expect?

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the H. C. Wainwright Global Investment Conference 2022 on Wednesday, May 25, 2022, at 12:00 PM ET.

Anavex Life Sciences to Present at the H. C. Wainwright Global Investment Conference 2022

Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer. Conference Call Participants Yun Zhong - BTIG Pete Stavropoulos - Cantor Operator Welcome to the Anavex Life Sciences Fiscal 2022 Second Quarter Conference Call.

Anavex Life Sciences Corp. (AVXL) CEO Christopher Missling on Q2 2022 Results - Earnings Call Transcript

Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Second Quarter Financial Results

San Diego, California--(Newsfile Corp. - May 6, 2022) - Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of federal securities laws by Anavex Life Sciences Corp. ("Anavex Life Sciences" or "the Company") (NASDAQ: AVXL).On February 1, 2022, Anavex Life Sciences announced a phase 3 trial of ANAVEX2-73 (blarcamesine) for Rett syndrome met primary and secondary endpoints. Following this news, a Senior Writer at Statnews stated, "Anavex changed the primary and secondary endpoints...

(AVXL) News: Did You Lose Money on Anavex Life Sciences Corp. Investment? Contact Johnson Fistel Regarding Class Action Investigation

Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET Webcast and Conference Call To be Held Tuesday May 10, 2022, 4:30 pm ET

Anavex Life Sciences to Announce Fiscal 2022 Second Quarter Financial Results on Tuesday May 10, 2022

Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett Syndrome Presentations cover the Psychometric Evaluation of the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Burden of Illness (BOI) Study in Rett Syndrome

Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Christopher U Missling, PhD, President & Chief Executive Officer of Anavex will present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on Wednesday, April 27, 2022, at 11:00 AM ET.

Anavex Life Sciences Invited to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference

NEW YORK, April 07, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that Anavex Management Team will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 3:45 PM ET.

Anavex Life Sciences to Present at the Needham Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)-- #ANAVEX273--WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Anavex Life Sciences Corp. (NASDAQ: AVXL) resulting from allegations that Anavex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Anavex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors With Losses to Inquire About Securities Class Action Investigation – AVXL

News for Anavex Life Sciences Stock (AVXL)